February 29, 2024 11:36 AM EST
News Briefing

Avid­i­ty to raise $400M; Sato pays Ar­cutis $25M up­front to li­cense top­i­cal rof­lu­mi­last in Japan

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics:

Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times